Cargando…

Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia

Essential thrombocythaemia (ET) is a rare myeloproliferative neoplasm. This multicentre, Phase 3b, randomised, open-label, non-inferiority study investigated the cardiac safety, efficacy and tolerability of first-line treatment with anagrelide or hydroxyurea in high-risk ET patients for up to 3 year...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gotic, Mirjana, Egyed, Miklos, Gercheva, Liana, Warzocha, Krzysztof, Kvasnicka, Hans Michael, Achenbach, Heinrich, Wu, Jingyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847982/ https://www.ncbi.nlm.nih.gov/pubmed/33123978 http://dx.doi.org/10.1007/s12012-020-09615-0

Ejemplares similares

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the TEAM‐ET 2·0 trial
por: Gisslinger, Heinz, et al.
Publicado: (2019)

Headache in essential thrombocythaemia
por: Frewin, R, et al.
Publicado: (2012)

Unrecognized pseudohyperkalaemia in essential thrombocythaemia
por: Mannu, Gurdeep Singh, et al.
Publicado: (2011)

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study
por: Birgegård, Gunnar, et al.
Publicado: (2018)

The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
por: Birgegård, Gunnar
Publicado: (2016)

Development and Validation of a Stability-Indicating RP-HPLC Method for the Quantitative Analysis of Anagrelide Hydrochloride
por: Pujeri, Sudhakar S., et al.
Publicado: (2012)

Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia
por: Morrell, Ruth, et al.
Publicado: (2013)

Herbaspirillum huttiense pneumonia in a patient with essential thrombocythaemia
por: Abreu-Di Berardino, Melanie, et al.
Publicado: (2019)

Can post-splenectomy thrombocytosis mask essential thrombocythaemia?
por: Langabeer, Stephen E.
Publicado: (2020)

Anagrelide‐induced pericardial effusion in a patient with essential thrombocythemia
por: Song, David, et al.
Publicado: (2023)

Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia
por: Pedersen, Oliver Buchhave, et al.
Publicado: (2022)

Leg Ulcers Associated with Anagrelide
por: Oskay, Tuba, et al.
Publicado: (2021)

Essential Thrombocythaemia with Concomitant Waldenström Macroglobulinaemia: Case Report and Literature Review
por: Lu, Nina, et al.
Publicado: (2020)

Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
por: Mathur, Abhinav, et al.
Publicado: (2022)

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study
por: Cascavilla, Nicola, et al.
Publicado: (2015)

Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels
por: Lewandowski, Krzysztof, et al.
Publicado: (2022)

Nadroparine-induced skin necrosis on a patient with essential thrombocythaemia: a case report
por: Pramateftakis, Manousos-Georgios, et al.
Publicado: (2009)

Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing
por: Angona, A, et al.
Publicado: (2016)

Can platelet count be controlled with ticagrelor in patients with essential thrombocythaemia? A case series
por: Yılmaz, Samet, et al.
Publicado: (2023)

Anagrelide-Induced Supraventricular Tachycardia: A Case Report
por: Badar, Faraz, et al.
Publicado: (2022)

Cardiovascular Safety of Anagrelide in Healthy Subjects: Effects of Caffeine and Food Intake on Pharmacokinetics and Adverse Reactions
por: Martínez-Sellés, Manuel, et al.
Publicado: (2012)

Postpartal recurrent non-ST elevation myocardial infarction in essential thrombocythaemia: case report and review of the literature
por: Arampatzis, Spyridon, et al.
Publicado: (2010)

Percutaneous coronary intervention in a patient with heparin resistance due to essential thrombocythaemia: a case report
por: Okabe, Toshitaka, et al.
Publicado: (2021)

Catastrophic antiphospholipid syndrome complicated with essential thrombocythaemia after COVID-19 vaccination: in search of the underlying mechanism
por: Jinno, Sadao, et al.
Publicado: (2021)

Anagrelide-associated Cardiomyopathy and Heart Failure in a Patient with Essential Thrombocythemia: A Case Report and Literature Review
por: Sugawara, Masafumi, et al.
Publicado: (2022)

Sustained Regression of Hydroxycarbamide Induced Actinic Keratoses after Switching to Anagrelide
por: Gaitanis, Georgios, et al.
Publicado: (2018)

Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2012)

Novel lysine‐specific histone demethylase 1 inhibitor in acute myeloid leukaemia transformed from essential thrombocythaemia
por: Hodges, Samantha, et al.
Publicado: (2021)

Development of acute myocardial infarction in a young female patient with essential thrombocythemia treated with anagrelide: a case report
por: Lim, Young-Hyo, et al.
Publicado: (2010)

Anagrelide Modulates Proplatelet Formation Resulting in Decreased Number and Increased Size of Platelets
por: Miyashita, Naohiro, et al.
Publicado: (2019)

Efficacy and safety of anagrelide as a first‐line drug in cytoreductive treatment‐naïve essential thrombocythemia patients in a real‐world setting
por: Ito, Tomoki, et al.
Publicado: (2019)

Prostaglandin cyclooxygenase products but not thromboxane A(2) are involved in the pathogenesis of ewthromelalgia in thrombocythaemia
por: Michiels, J. J., et al.
Publicado: (1993)

Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera
por: Tiong, I S, et al.
Publicado: (2016)

A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment
por: Byun, Ja Min, et al.
Publicado: (2022)

TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders
por: Palmblad, Jan, et al.
Publicado: (2008)

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)
por: Okikiolu, Jumoke, et al.
Publicado: (2022)

Rescue balloon pulmonary angioplasty for worsening chronic thromboembolic pulmonary hypertension with essential thrombocythaemia and the JAK2-V617F mutation: a case report
por: Tamura, Hiroto, et al.
Publicado: (2023)

Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France
por: Rey, Jérôme, et al.
Publicado: (2014)

Pharmacokinetics of a Novel Anagrelide Extended‐Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product
por: Petrides, Petro E., et al.
Publicado: (2017)

An Ulceronecrotic Foot Lesion in a Patient with Essential Thrombocythemia: Successful Treatment with Hydroxyurea
por: Kato, Tokue, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_isbsqrbntjolbrubpsvcmd8jp9